NCT07181486RecruitingPhase 1
Safety Study of MucoCept-CVN
Phase 1 Randomized Double-Blind Placebo-Controlled Safety Study of MucoCept-CVN (Lactobacillus Jensenii 1153-1666) Administered Vaginally to Healthy Women
Source: ClinicalTrials.gov · Last updated 16 Oct 2026
Brief summary (registry, in English)
MucoCept-CVN uses a Lactobacillus strain native to the human vagina that is modified into a live biotherapeutic product (LBP) that continuously expresses a potent anti-HIV drug. If research shows that MucoCept-CVN is safe and effective, it could become a self-renewing, female-initiated prevention product for women that promotes vaginal health and provides protection from HIV. The goal of this first-in-human Phase 1 dose-ranging, randomized, placebo-controlled study of MucoCept-CVN is to collect data on safety, colonization, changes to the vaginal microbiota and clearance of the strain with antibiotics. Twelve healthy women will be enrolled and take either one or three doses of MucoCept-CVN or placebo, and a week later will receive antibiotics to clear the Lactobacillus strain. If research shows that MucoCept-CVN is safe and effective, it could become a self-renewing, long-acting, female-initiated prevention product for women that promotes vaginal health and provides protection from HIV.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- First submitted
- 11 Sept 2025
- Start date
- 6 Oct 2025
- Primary completion date
- 30 Apr 2027
- Lead sponsor
- Craig Cohen, MD, MPH
- Diseases
- HIV
- NCT number
- NCT07181486
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 12
- From 6 Oct 2025 to the primary completion date, 30 Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Antibiotic or antifungal therapy (vaginal or systemic) within 30 days of enrollment
- Investigational or immune-suppressive drug use within 30 days of enrollment visit or 10 half-lives, or planned during the study
- Intrauterine device insertion or removal, pelvic surgery, cervical cryotherapy, cervical laser or loop electrosurgical procedure, abortion, labioplasty within three months prior to enrollment
- If in a sexual relationship, having multiple concurrent partners or anonymous partners.
- Having multiple concurrent sex partners or anonymous sex partners.
- Co-enrollment in clinical trials testing study drugs
Other illness
- Urogenital infection, including UTI, Trichomonas vaginalis, Neisseria gonorrhoeae, Chlamydia trachomatis, Treponema pallidum, HIV-1/2, BV, or vulvovaginal candidiasis
- Known allergy to any component used in MucoCept-CVN or clindamycin and azithromycin in participant or sexual partner(s), including azithromycin-associated cholestatic jaundice.
- History of transplant surgery, cancer, HIV, diabetes or condition that could facilitate the growth of microorganisms
- Recent history of drug or alcohol abuse
- Any other condition which the study clinician feels would limit the participant's ability to be an appropriate study subject
- History of regional enteritis (Crohn's disease), ulcerative colitis, or "antibiotic-associated" colitis
- For sexual partners of study participants, the following exclusion criteria apply:
- Known allergy to any component used in MucoCept-CVN or clindamycin and azithromycin, including azithromycin-associated cholestatic jaundice.
- HIV-1/2 infection
- Any other condition which the study clinician feels would limit the ability of sexual partner(s) to complete the study
Other
- Abnormal Pap smear result
- Pregnancy or within two months of last pregnancy or lactation
- Findings during the pelvic exam at the enrollment visit involving significant deep disruption of the epithelium (e.g., Herpes genitalis lesions)
- Unwillingness to abstain from sexual activity during study by participant or sexual partner(s)
- If in a sexual relationship, inability to present with their sexual partner before enrollment
Who the study is looking for
- Healthy pre-menopausal women 18-45 years of age, inclusive, with regular predictable menstrual cycles
- Ability to read and consent in English
- Previous experience of gynecological examinations
- Consent to participate and adhere to all procedures, including frequent visits at the UCSF Clinical Research Center (CRC) facility for at least 53 days
- Agree to get tested for STIs and a Pap Smear
- Agree not to use any other vaginal product during the course of the study, including spermicides
- Agree to sexual abstinence (no vaginal, anal, and receptive oral intercourse) until the elimination of L. jensenii 1153-1666 is confirmed and for 12 hours prior to the final study visit after clearance is confirmed
- For participants with male sexual partners: Agree to use two forms of contraception, condoms plus hormonal or permanent method (intrauterine device \[IUD\] or tubal ligation) during vaginal intercourse from the time clearance is established to the Final Visit 30 days after clearance. Use of spermicides is not permitted.
- For participants with female sexual partners: Agree to use female condoms during intercourse from the time clearance is established to the Final Visit 30 days after clearance. Use of hormonal or permanent method of contraception (IUD or tubal ligation) is not required.
- Agree to inform their sexual partner about the goals of the study and importance of sexual abstinence (no vaginal, anal, and receptive oral intercourse) and present with their partner at enrollment visit for separate consent procedure for partners
- Current sexual partners of participants must meet all the following criteria to be enrolled:
- Ability to read and consent in English
- Consent to participate and adhere to all procedures for sexual partners should exposure to L. jensenii 1153-1666 be suspected, including multiple visits at the UCSF Clinical Research Center (CRC)
- Agree to sexual abstinence (no vaginal, anal, and receptive oral intercourse) until the elimination of L. jensenii 1153-1666 is confirmed, and for 12 hours prior to the final study visit after clearance is confirmed
Age in the registry: 18 years to 45 years · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UCSF Zuckerberg San Francisco General Hospital Coordinator of this site? Confirm its status | San Francisco | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.